Insulet Corp. soared as the Bedford company posted quarterly results. Revenue increased 20 percent to $57.4 million from a year earlier, and gross profit was up 24 percent to $25.2 million. Those increases, the company said, were driven by sales of the new, smaller, and lighter OmniPod Insulin Management System for diabetics, launched in the United States in February. Insulet’s net loss was $10.7 million, or $0.20 per share, compared to a net loss of $14.8 million, or $0.31, a year earlier.
Insulet boosts sales, narrows its net loss
May 08, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢